AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases. AC Immune SA develops therapeutic and diagnostic products designed to address disorders linked to protein misfolding, with a current emphasis on Alzheimer’s disease, Parkinson’s disease, ALS, and selected rare neurodegenerative conditions. Its work centers on proprietary technology platforms that support the discovery of antibodies, small molecules, vaccines, and imaging agents intended for early detection, treatment, and prevention. The company’s pipeline spans both therapeutic and diagnostic programs, reflecting a dual approach to understanding disease biology and creating targeted interventions. AC Immune SA also collaborates with pharmaceutical and research partners to advance its programs across neurodegenerative markets. Headquartered in Lausanne, Switzerland, AC Immune SA plays a specialized role in the biotechnology sector by developing tools and treatments aimed at some of the most complex and underserved diseases of the nervous system.
$2.39
-$0.06 (-2.45%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-1927.32% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 86.9% YoY. Margins deteriorated 1735.5pp alongside, both lines moving the wrong way.
Free cash flow declined 208% versus the prior year, cash generation momentum has weakened. ROIC dropped from -29.36% to -65.10%, capital efficiency is deteriorating.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
CHF 18M
▼ -86.9% YoY
Net Income (TTM)
-CHF 43M
▼ -38.4% YoY
Op. Margin
-249.59%
▼ -1735.5pp YoY
ROIC
-65.10%
▼ -35.7pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-CHF 70M
▼ -207.5% YoY
Op. Cash Flow (FY)
-CHF 69M
▼ -205.2% YoY
Net Debt
-CHF 87M
Net Cash Position
Cash & Equiv.
CHF 91M
3Y CAGR: -3.2%
Continue Research
Is AC Immune SA (ACIU) overvalued?
AC Immune SA (ACIU)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, AC Immune SA scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is AC Immune SA a high-quality business?+
AC Immune SA scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -249.6% operating margin and a -65.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is AC Immune SA a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh ACIU's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.